Aptevo Therapeutics (NASDAQ:APVO) Upgraded at Wall Street Zen

Aptevo Therapeutics (NASDAQ:APVO) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Aptevo Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aptevo Therapeutics has a consensus rating of “Hold”.

Aptevo Therapeutics Price Performance

APVO stock opened at $7.32 on Friday. Aptevo Therapeutics has a 1 year low of $5.94 and a 1 year high of $1,439.96. The company has a market cap of $7.32 million, a P/E ratio of 0.00 and a beta of 1.49. The stock’s fifty day moving average price is $8.85 and its 200-day moving average price is $20.87.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Birchview Capital LP acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned approximately 1.32% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is owned by institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.